TISIDB

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
Domain	PF08423 Rad51
Function	Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA, thought to repair chromosomal fragmentation, translocations and deletions. Part of the Rad21 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0000707 meiotic DNA recombinase assembly GO:0000724 double-strand break repair via homologous recombination GO:0000725 recombinational repair GO:0000730 DNA recombinase assembly GO:0000731 DNA synthesis involved in DNA repair GO:0000732 strand displacement GO:0001701 in utero embryonic development GO:0001756 somitogenesis GO:0003002 regionalization GO:0006302 double-strand break repair GO:0006310 DNA recombination GO:0006312 mitotic recombination GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007131 reciprocal meiotic recombination GO:0007389 pattern specification process GO:0009314 response to radiation GO:0009952 anterior/posterior pattern specification GO:0010165 response to X-ray GO:0010212 response to ionizing radiation GO:0010332 response to gamma radiation GO:0010720 positive regulation of cell development GO:0031023 microtubule organizing center organization GO:0035264 multicellular organism growth GO:0035282 segmentation GO:0035825 reciprocal DNA recombination GO:0042148 strand invasion GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0044346 fibroblast apoptotic process GO:0045003 double-strand break repair via synthesis-dependent strand annealing GO:0050769 positive regulation of neurogenesis GO:0051297 centrosome organization GO:0051321 meiotic cell cycle GO:0051402 neuron apoptotic process GO:0051962 positive regulation of nervous system development GO:0061053 somite development GO:0065004 protein-DNA complex assembly GO:0070997 neuron death GO:0071824 protein-DNA complex subunit organization GO:0071897 DNA biosynthetic process GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1903046 meiotic cell cycle process GO:2000269 regulation of fibroblast apoptotic process
Molecular Function	GO:0000150 recombinase activity GO:0000217 DNA secondary structure binding GO:0000400 four-way junction DNA binding GO:0003697 single-stranded DNA binding GO:0004518 nuclease activity GO:0004519 endonuclease activity GO:0004520 endodeoxyribonuclease activity GO:0004536 deoxyribonuclease activity GO:0008094 DNA-dependent ATPase activity GO:0016887 ATPase activity GO:0042623 ATPase activity, coupled GO:0043566 structure-specific DNA binding
Cellular Component	GO:0005657 replication fork GO:0005813 centrosome GO:0033061 DNA recombinase mediator complex GO:0033063 Rad51B-Rad51C-Rad51D-XRCC2 complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03440 Homologous recombination
Reactome	R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) R-HSA-5685942: HDR through Homologous Recombination (HRR) R-HSA-5693579: Homologous DNA Pairing and Strand Exchange R-HSA-5693538: Homology Directed Repair R-HSA-5693616: Presynaptic phase of homologous DNA pairing and strand exchange R-HSA-5693537: Resolution of D-Loop Structures R-HSA-5693568: Resolution of D-loop Structures through Holliday Junction Intermediates R-HSA-5693554: Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03440 Homologous recombination

Reactome

R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5685942: HDR through Homologous Recombination (HRR)
R-HSA-5693579: Homologous DNA Pairing and Strand Exchange
R-HSA-5693538: Homology Directed Repair
R-HSA-5693616: Presynaptic phase of homologous DNA pairing and strand exchange
R-HSA-5693537: Resolution of D-Loop Structures
R-HSA-5693568: Resolution of D-loop Structures through Holliday Junction Intermediates
R-HSA-5693554: Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between XRCC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of XRCC2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.26; FDR: 0.04180	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of XRCC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.352	0.242
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.126	0.827
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.528	0.352
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.128	0.732
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.153	0.901
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.094	0.952
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.069	0.853
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.583	0.524
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.691	0.388
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.385	0.418
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.162	0.801
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.414	0.00137

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of XRCC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of XRCC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of XRCC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by XRCC2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of XRCC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of XRCC2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between XRCC2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	XRCC2
Name	X-ray repair complementing defective repair in Chinese hamster cells 2
Aliases	X-ray repair cross-complementing protein 2; DNA repair protein XRCC2
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting XRCC2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse XRCC2